Canada markets open in 3 hours 10 minutes

Panbela Therapeutics, Inc. (PBLA)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.6700+0.0600 (+3.73%)
At close: 03:56PM EDT
Sign in to post a message.
  • S
    Suez
    Added another 10k shares, which bring my total to 34k shares. I'm tapped out. Risk is high but reward is delightful!
  • V
    ValuFin
    They are adding the ovarian cancer market to their pipeline by imminently starting a clinical trial for that population, that is yet another huge market to be accounted for.
  • M
    Michael
    We need a cure for pancreatic cancer quickly! Sun BioPharma is in clinical trials making great strides at providing a solution to treat pancreatic cancer.

    The late Supreme Court Justice Ruth Bader Ginsburg and US Democratic Representative John Lewis both were diagnosed with metastatic pancreatic cancer, one of the deadliest cancers in the USA.

    There are currently no general screening tools for pancreatic cancer, and there are often no symptoms in the early stages, when the tumor would be most treatable.
  • r
    rarecoin
    Lesson here is I NEVER buy a stock at 52 wk highs with no reason why it's up. P&D stock
  • S
    Stanislav
    1.PBLA - public release of additional data from phase 1 trial – ASCO Annual Meeting June 4-8, 2021
    2. PBLA is extreme high-risk, high-reward low floater. GLSI run from $5 to $150 and APVO from $6 to $80.
    3. PBLA Shares Outstanding (Company) 9.65M
    Held by Insiders 19.14%

    4. Do your own due diligence!
  • S
    Stanislav
    1.Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (SBFM) (Nasdaq: SNBP): »Based on interim data from our Phase I trial, SBP-101 demonstrated a 54% objective response rate in combination with gemcitabine & abraxane (G&A); more than double historical standard of care for metastatic pancreatic cancer with G&A«.
    2. Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (SBFM) (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics (PBLA), Inc. effective December 2, 2020
    3. Dec. 08, 2020 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA): "We are pleased to have completed enrollment in our Phase 1b trial and expect to announce data in the first half of next year,” commented Jennifer Simpson, PhD., M.S.N., C.R.N.P. - President & Chief Executive Officer.
    4. PBLA is low floater.
    Shares Outstanding (Company) 9.65M
    Held by Insiders 19.14%

    5. Do your own due diligence.
  • M
    Michael
    Craig-Hallum bullish on Sun BioPharma (SNBP) trading on the NASDAQ, initiates with a Buy As previously reported, Craig-Hallum analyst Robin Garner initiated coverage of Sun BioPharma with a Buy rating and $9 price target.

    The analyst sees great value in Sun BioPharma at current market cap since the Phase I data are outstanding in a field that is otherwise characterized by failures and most healthcare investors are unaware of it.

    The U.S. metastatic pancreatic cancer market is expected to reach $3B by 2025, he notes, adding that there is high demand for new therapeutics that are well tolerated and can enhance the effectiveness of existing chemotherapy agents that only extend life by a few months.
  • S
    Stanislav
    1. Dec. 08, 2020 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA): "We are pleased to have completed enrollment in our Phase 1b trial and expect to announce data in the first half of next year,” commented Jennifer Simpson, PhD., M.S.N., C.R.N.P. - President & Chief Executive Officer.
    2. PBLA is waiting for data. GLSI run from $5 to $150 and APVO from $6 to $80. PBLA is extreme high-risk, high-reward low floater. Do Your Own Due Diligence.
    3.Do your own due diligence.
  • M
    Michael
    $SNBP Wow, amazing data for treating Pancreatic Cancer!! News from the Phase I trial, SBP-101 The drug in clinical trials just demonstrated a 54% objective response rate in combination with Gemcitabine & Abraxane (G&A); more than double historical standard of care for metastatic pancreatic cancer with G&A. This is revolutionary news!! Buy, Buy, Buy!!
  • H
    Harry
    Just got in at $6 today when the market dip, what's your price target and how confident you guys are?
  • M
    Mike
    I need your opinion i bought it at $8 i am down a lot should i sell for a lost or hold? Honest opinion please.
  • Z
    Zafer
    Monday is holiday for nasdaq, 18th Tuesday is the relase date of PR presentation Asco, low float and theu have different types of very important cancer studies. Generally stocks react much more during first PR relase.
  • A
    Anonymous
    looks like hype from recent articles. Will be buying back under 3 shortly.
  • S
    Stephen
    New GLSI
  • M
    Michael
    Sun BioPharma SNBP - finally got major financing in place today. They are now able to move forward much faster with their revolutionary Pancreatic cancer drug candidate. This is such exciting news to have a contender in the ring that looks like it can beat this awful cancer.
  • M
    Majorette Garrett You Are a SISSY
    What in the world? I sold mine today at 3.60!
  • S
    Schimanski
    $3.15 nice
  • s
    sruly
    Reversal incoming……
  • V
    ValuFin
    They just acquired 3 pipelines of which an NDA and a phase 3 trial in colon cancer, for a very low dilution price. Insane that the whole market cap is lingering below $50M. Should be multiples that.
  • L
    Lim
    how come no volume